Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]
Thromb Res. 2022 May:213:113.
doi: 10.1016/j.thromres.2022.03.012.
Epub 2022 Mar 22.
1 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
2 Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands.
3 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Thrombosis Expertise Centre, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.
4 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands. Electronic address: [email protected].